



October 26, 2020

**VIA E-FILING**

The Honorable Colm F. Connolly  
J. Caleb Boggs Federal Building  
844 N. King Street  
Room 4124; Unit 31  
Wilmington, DE 19801-3555

**RE: *Par Pharmaceutical Inc., et al. v. Eagle Pharmaceuticals Inc.***  
**C.A. No. 18-cv-823-CFC-JLH**

Dear Judge Connolly:

We represent Plaintiffs in the above-captioned Hatch-Waxman Act case, in which defendant Eagle Pharmaceuticals seeks FDA approval to launch a generic version of plaintiff Par Pharmaceuticals' Vasostrict® product. By letter dated October 7, 2020, the parties jointly wrote the Court to request a scheduling conference in view of the fact that the expiration of the 30-month stay of final approval of Eagle's ANDA was imminent. D.I. 205. In response, the Court has scheduled a teleconference for October 28 at 11:00 am.

In advance of the status conference, we wish to apprise the Court of the status of Eagle's application with the FDA. A chronology is set forth in the appendix at the end of this letter.

In short, the best information we have is that we can expect

of its ANDA

Given the realities of FDA review

Respectfully submitted,

/s/ Michael J. Farnan

Michael J. Farnan

cc: Counsel of Record (Via E-Mail)